Use of the synbiotic VSL#3 and yacon-based concentrate attenuates intestinal damage and reduces the abundance of Candidatus Saccharimonas in a colitis-associated carcinogenesis model. (November 2020)

• Record Type: Journal Article
• Authors: Cruz, Bruna Cristina dos Santos; Conceição, Lisiane Lopes da; Mendes, Tiago Antônio de Oliveira; Ferreira, Célia Lúcia de Luces Fortes; Gonçalves, Reggiani Vilela; Peluzio, Maria do Carmo Gouveia
• Is Part Of: Food research international. Volume 137(2020)
• Publication Date: 2020-11
• Subjects: Synbiotic -- Colitis -- Colorectal câncer -- Inflammatory bowel disease -- Gut microbiota -- Dysbiosis; IBD inflammatory bowel disease -- CRC colorectal cancer -- CAC colitis-associated cancer -- PBY yacon-based product -- DSS dextran sulfate sodium -- TNBS trinitrobenzene sulfonic acid -- FOS fructooligosaccharides -- HPLC high performance liquid chromatography -- DMH 1, 2-dimethylhydrazine -- CFE food efficiency -- SCFA short chain-fatty acid -- DAI disease activity index -- TNF tumor necrosis factor -- UC ulcerative colitis -- CD Crohn's disease -- MDA malondialdehyde -- CP carbonyls protein; Food -- Analysis -- Periodicals; Food industry and trade -- Periodicals; Food industry and trade -- Canada -- Periodicals; Food Technology -- Periodicals; Food -- Periodicals; Food-Processing Industry -- Periodicals; Aliments -- Industrie et commerce -- Périodiques; Aliments -- Industrie et commerce -- Canada -- Périodiques; Aliments -- Recherche -- Périodiques; Food industry and trade; Canada; Periodicals; Electronic journals; 664.005
• DOI: 10.1016/j.foodres.2020.109721
• Languages: English
• ISSNs: 0963-9969

Abstract

Graphical abstract: Highlights: Synbiotic positively modulates hepatic antioxidants enzymes activity in a CAC model. Synbiotic changes the microbial community in a CAC model. Synbiotic reduces relative abundance of Candidatus Saccharimonas in a CAC model. Synbiotic increases the fecal short-chain fatty acids in a CAC model. Abstract: Individuals with inflammatory bowel disease are at high risk of developing colitis-associated cancer; thus, strategies to inhibit disease progression should be investigated. The study aimed to explore the role of the synbiotic (probiotic VSL#3® and yacon-based concentrate) in a colitis-associated carcinogenesis model. IL-10 −/− mice were induced to carcinogenesis with 1, 2-dimethylhydrazine and divided into two experimental groups: control and synbiotic. Manifestations of colitis, colon histology, expression of antioxidant enzymes, production of organic acids and intestinal microbiota were evaluated. The use of the synbiotic showed benefits, such as the preservation of intestinal architecture, increased expression of antioxidant enzymes and the concentration of organic acids, especially butyrate. It was also observed different microbial community profiles between the groups during the study. Together, these factors contributed to mitigate the manifestations of colitis and improve intestinal integrity, suggesting the potential benefit of the synbiotic in intestinal diseases.